Description
Dyslipidemia is a key contributor to endothelial dysfunction, which underlies the development of atherosclerosis, thrombosis, insulin resistance, and hypertension. Routine check-ups often uncover hidden hyperlipidemia and ASCVD risk. This case review CME presents a similar scenario involving a 54-year-old patient, initiated on Roshal (rosuvastatin 10 mg) and scheduled for follow-up after three months.
Explore the full case review CME to learn more about the patient’s outcome.